Recommended Subcutaneous Semaglutide Dosing for Obesity Without Type 2 Diabetes
For adults with obesity without diabetes, start subcutaneous semaglutide at 0.25 mg once weekly, then escalate monthly to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg weekly, reaching the maintenance dose at 16 weeks. 1, 2
Detailed Titration Schedule
The dosing follows a structured 5-step escalation protocol:
- Weeks 1-4: 0.25 mg once weekly
- Weeks 5-8: 0.5 mg once weekly
- Weeks 9-12: 1.0 mg once weekly
- Weeks 13-16: 1.7 mg once weekly
- Week 17 onward: 2.4 mg once weekly (maintenance dose)
This gradual titration is specifically designed to minimize gastrointestinal adverse effects, particularly nausea and vomiting, which are the most common side effects 1.
Administration Details
- Inject subcutaneously in the abdomen, thigh, or upper arm 3
- Administer once weekly at any time of day, with or without meals 3
- If a dose is missed, administer within 5 days of the missed dose 3
Dose Adjustment Considerations
Clinical judgment should guide individual titration adjustments. Some patients achieve excellent response at submaximal doses (e.g., 1.0 mg or 1.7 mg weekly) and can continue that dose long-term rather than escalating to 2.4 mg 1.
Missed Dose Protocol
- 2 consecutive doses missed: Resume at the same dose if previously well-tolerated; otherwise consider lowering the dose 1
- 3+ consecutive doses missed: Restart the entire titration schedule from 0.25 mg 1
Expected Outcomes
At the 2.4 mg maintenance dose, expect:
- Mean weight loss: 14.9-16.9% at 68 weeks 2, 4
- ≥5% weight loss: Achieved by 86.4% of patients 4
- ≥15% weight loss: Achieved by 50.5% of patients 4
Critical Safety Considerations
Gastrointestinal adverse effects (nausea 40%, vomiting 16%) are significantly more common than placebo but typically transient and mild-to-moderate, subsiding with time 1. The gradual monthly titration is essential to minimize these effects.
Do not use semaglutide with:
- Other GLP-1 receptor agonists
- DPP-4 inhibitors 1
Contraindication: Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (thyroid C-cell tumor risk demonstrated in rodents) 1, 3.